Rare Disease Portfolio: Best Proven Growth Strategies
Rare disease portfolio growth is crucial for pharma companies. Explore Shionogi’s $2B acquisition of IntraBio and its implications.
Rare disease portfolio growth is crucial for pharma companies. Explore Shionogi’s $2B acquisition of IntraBio and its implications.
Bliss GVS Pharma acquisition marks a significant shift in the market dynamics.
Milestone Pharmaceuticals stock remains steady at $0.92 following China approval, showing potential for growth in the pharmaceutical market.
Medical consumable price gaps are alarming, as highlighted by Maharashtra FDA Chief IAS Tukaram Mundhe’s findings.
